StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results

- StockWatch: Agilent (A) surged 17% on Q2 beats. But the real story? AI’s reshaping the wet lab. CEO McDonnell notes pharma is leaning into AI to cut late-stage failures, driving demand for high-throughput tools and multi-omics data. J.P. Morgan sees AI shortening target ID, boosting validation volume for Agilent’s instruments. It’s not just chromatography; it’s data infrastructure for drug discovery. With GLP-1 tool purchases up 20% and strong LC replacement cycles, Agilent sits at the intersection of biotech hardware and AI-driven efficiency. A clean “tools story” where digital intelligence meets physical validation. Odd charm: The lab bench is becoming a server rack.